| http://www.w3.org/ns/prov#value | - Accordingly, an embodiment of the invention is an anti-EGFR polypeptide comprising a single domain antibody or Nanobody specifically binding to the ectodomain of EGFR and competing with the EGF and TGF?? binding site on EGFR, but not with the Erbitux binding site on EGFR. Another embodiment of the invention is an anti-EGFR polypeptide comprising a single domain antibody or Nanobody specifically bi
|
